Serum Endocan Levels in Patients with Age-related Macular Degeneration
Yıl: 2018 Cilt: 27 Sayı: 2 Sayfa Aralığı: 158 - 161 Metin Dili: İngilizce İndeks Tarihi: 08-05-2019
Serum Endocan Levels in Patients with Age-related Macular Degeneration
Öz: Aim: Our aim was to compare the serum endocan levels of wet and dry type age-related macular degeneration (AMD) patients withcontrol subjects.Materials and Methods: This cross-sectional case control study was conducted on a total of 89 subjects consisting of 26 wet type AMDand 30 dry type AMD cases and 33 control subjects. Serum endocan levels were measured by an enzyme-linked immunosorbent assaykit in all participants.Results: There was no signifi cant difference among the groups for mean age, gender distribution or body mass index (p>0.05). Serumendocan levels were 15.7±6 ng/mL, 16±5.7 ng/mL and 18.1±5.3 ng/mL in wet and dry type AMD patients and control subjects, respec-tively, with no signifi cant difference among the groups (p=0.192).Conclusion: We did not fi nd a signifi cant difference in serum endocan levels between wet and dry type AMD patients and controlsubjects. However, further studies evaluating vitreous endocan levels are needed to investigate the potential pathophysiological role ofendocan in AMD pathogenesis.
Anahtar Kelime: Konular:
Yaşa Bağlı Maküla Dejenerasyonu Olan Hastalarda Serum Endocan Seviyeleri
Öz: Amaç: Amacımız yaş ve kuru tip yaşa bağlı maküla dejenerasyonu (YBMD) olan hastalarda serum endocan seviyelerini kontrollerle karşılaştırmaktır. Gereç ve Yöntem: Bu kesitsel vaka kontrol çalışması, 26 yaş tip YBMD, 30 kuru tip YBMD ve 33 kontrolden oluşan, toplam 89 gönüllü üzerinde gerçekleştirilmiştir. Serum endocan seviyeleri tüm olgularda bir ELISA kit ile değerlendirilmiştir. Bulgular: Ortalama yaş, cinsiyet dağılımı ve vücut kitle indeksi açısından gruplar arasında anlamlı bir farklılık yoktu (p>0.05). Serum endocan seviyeleri yaş ve kuru tip YBMD hastalarında ve kontrollerde sırasıyla 15.7±6 ng/mL, 16±5.7 ng/mL ve 18.1±5.3 ng/mL idi ve gruplar arasında anlamlı farklılık yoktu (p=0.192). Sonuç: Yaş ve kuru tip YBMD hastaları ve kontroller arasında serum endocan seviyeleri açısından anlamlı bir fark bulmadık. Ancak, YBMD patogenezindeki endocan’ın patofi zyolojik rolünü araştırmak için vitreus endocan seviyelerini değerlendiren ileri çalışmalara ihtiyaç vardır.
Anahtar Kelime: Konular:
Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Bibliyografik
- Chang TS, Aylwaed GW, Davis JL, et al. İdiopatic retinal vascu1. Friedman DS, O’Colmain BJ, Muñoz B, et al; Eye Diseases Pre- valence Research Group. Prevalence of age-related macular dege- neration in the United States. Arch Ophthalmol 2004;122:564-72.
- Nowak JZ. Age-related macular degeneration (AMD): pathogene- sis and therapy. Pharmacol Rep 2006;58:353-63.
- Sarrazin S, Adam E, Lyon M, et al. Endocan or endothelial cell specifi c molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. Biochim Biophys Acta 2006;1765:25-37.
- Lassalle P, Molet S, Janin A, et al. ESM-1 is a novel human endo- thelial cell-specifi c molecule expressed in lung and regulated by cytokines. J Biol Chem 1996;271:20458-64.
- Kechagia M, Papassotiriou I, Gourgoulianis KI. Endocan and the respiratory system: a review. Int J Chron Obstruct Pulmon Dis. 2016;11:3179-87.
- Kali A, Shetty KS. Endocan: a novel circulating proteoglycan. In- dian J Pharmacol 2014;46:579-83.
- Zuo L, et al. Correlation between expression and differentiation of endocan in colorectal cancer. World J Gastroenterol 2008;14:4562– 8.
- Kılıç R, Kurt A, Tad M, et al. Endocan overexpression in pterygi- um. Cornea 2017;36:696-9.
- Bird AC, Bressler NM, Bressler SB, et al. An international clas- sifi cation and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epide- miological Study Group. Surv Ophthalmol 1995;39:367-74.
- Mata NL, Vogel R. Pharmacologic treatment of atrophic age-rela- ted macular degeneration. Curr Opin Ophthalmol 2010;21:190-6.
- Biarnés M, Monés J, Alonso J, et al. Update on geographic atrophy in age-related macular degeneration. Optom Vis Sci 2011;88:881- 9.
- Velez-Montoya R, Oliver SC, Olson JL, et al. Current knowledge and trends in age-related macular degeneration: today’s and future treatments. Retina 2013;33:1487-502.
- Velez-Montoya R, Oliver SC, Olson JL, et al. Current knowledge and trends in age-related macular degeneration: genetics, epidemi- ology, and prevention. Retina 2014;34:423-441.
- Sarrazin S, Lyon M, Deakin JA, et al. Characterization and binding activity of the chondroitin/dermatan sulfate chain from Endocan, a soluble endothelial proteoglycan. Glycobiology 2010;20:1380-8.
- Rennel E, Mellberg S, Dimberg A, et al. Endocan is a VEGF-A and PI3K regulated gene with increased expression in human renal cancer. Exp Cell Res 2007;313:1285-94.
- Shin JW, Huggenberger R, Detmar M. Transcriptional profi ling of VEGF-A and VEGF-C target genes in lymphatic endothelium reveals endothelial-specifi c molecule-1 as a novel mediator of ly- mphangiogenesis. Blood 2008;112:2318-26.
- Balta S, Mikhailidis DP, Demirkol S, et al. Endocan: A novel inf- lammatory indicator in cardiovascular disease? Atherosclerosis 2015;243:339-43.
- Scherpereel A, Depontieu F, Grigoriu B, et al. Endocan, a new en- dothelial marker in human sepsis. Crit Care Med 2006;34:532-7.
- Mihajlovic DM, Lendak DF, Brkic SV, et al. Endocan is use- ful biomarker of survival and severity in sepsis. Microvasc Res 2014;93:92-7.
- Pauly D, Hamed S, Behnes M, et al. Endothelial cell-specifi c mo- lecule-1/endocan: Diagnostic and prognostic value in patients suf- fering from severe sepsis and septic shock. J Crit Care 2016;31:68- 75.
- Seo K, Kitazawa T, Yoshino Y, et al. Characteristics of serum en- docan levels in infection. PLoS One 2015;10:e0123358.
- Cox LA, van Eijk LT, Ramakers BP, et al. Infl ammation-induced increases in plasma endocan levels are associated with endothelial dysfunction in humans in vivo. Shock 2015;43:322-6.
- Huang GW, Tao YM, Ding X. Endocan expression correlated with poor survival in human hepatocellular carcinoma. Dig Dis Sci 2009;54:389-94.
- Lee WL, Slutsky AS. Sepsis and endothelial permeability. N Engl J Med 2010;363:689-91.
- Balta I, Balta S, Koryurek OM, et al. Serum endocan levels as a marker of disease activity in patients with Behçet disease. J Am Acad Dermatol 2014;70:291-6.
- Grigoriu BD, Depontieu F, Scherpereel A, et al. Endocan expres- sion and relationship with survival in human non-small cell lung cancer. Clin Cancer Res 2006;12:4575-82.
- Chen M, Xu H. Parainfl ammation, chronic infl ammation, and age-related macular degeneration. J Leukoc Biol. 2015;98:713-25.
- Abu El-Asrar AM, Nawaz MI, De Hertogh G, et al. The angioge- nic biomarker endocan is upregulated in proliferative diabetic re- tinopathy and correlates with vascular endothelial growth factor. Curr Eye Res 2015;40:321-31.
| APA | KILIÇ R, Kurt A, nar r, kocamis o, TAŞDEMİR S, POLAT O (2018). Serum Endocan Levels in Patients with Age-related Macular Degeneration. , 158 - 161. |
| Chicago | KILIÇ Raşit,Kurt Ali,nar rukiye,kocamis ozkan,TAŞDEMİR Sedat,POLAT Osman Ahmet Serum Endocan Levels in Patients with Age-related Macular Degeneration. (2018): 158 - 161. |
| MLA | KILIÇ Raşit,Kurt Ali,nar rukiye,kocamis ozkan,TAŞDEMİR Sedat,POLAT Osman Ahmet Serum Endocan Levels in Patients with Age-related Macular Degeneration. , 2018, ss.158 - 161. |
| AMA | KILIÇ R,Kurt A,nar r,kocamis o,TAŞDEMİR S,POLAT O Serum Endocan Levels in Patients with Age-related Macular Degeneration. . 2018; 158 - 161. |
| Vancouver | KILIÇ R,Kurt A,nar r,kocamis o,TAŞDEMİR S,POLAT O Serum Endocan Levels in Patients with Age-related Macular Degeneration. . 2018; 158 - 161. |
| IEEE | KILIÇ R,Kurt A,nar r,kocamis o,TAŞDEMİR S,POLAT O "Serum Endocan Levels in Patients with Age-related Macular Degeneration." , ss.158 - 161, 2018. |
| ISNAD | KILIÇ, Raşit vd. "Serum Endocan Levels in Patients with Age-related Macular Degeneration". (2018), 158-161. |
| APA | KILIÇ R, Kurt A, nar r, kocamis o, TAŞDEMİR S, POLAT O (2018). Serum Endocan Levels in Patients with Age-related Macular Degeneration. Retina-Vitreus, 27(2), 158 - 161. |
| Chicago | KILIÇ Raşit,Kurt Ali,nar rukiye,kocamis ozkan,TAŞDEMİR Sedat,POLAT Osman Ahmet Serum Endocan Levels in Patients with Age-related Macular Degeneration. Retina-Vitreus 27, no.2 (2018): 158 - 161. |
| MLA | KILIÇ Raşit,Kurt Ali,nar rukiye,kocamis ozkan,TAŞDEMİR Sedat,POLAT Osman Ahmet Serum Endocan Levels in Patients with Age-related Macular Degeneration. Retina-Vitreus, vol.27, no.2, 2018, ss.158 - 161. |
| AMA | KILIÇ R,Kurt A,nar r,kocamis o,TAŞDEMİR S,POLAT O Serum Endocan Levels in Patients with Age-related Macular Degeneration. Retina-Vitreus. 2018; 27(2): 158 - 161. |
| Vancouver | KILIÇ R,Kurt A,nar r,kocamis o,TAŞDEMİR S,POLAT O Serum Endocan Levels in Patients with Age-related Macular Degeneration. Retina-Vitreus. 2018; 27(2): 158 - 161. |
| IEEE | KILIÇ R,Kurt A,nar r,kocamis o,TAŞDEMİR S,POLAT O "Serum Endocan Levels in Patients with Age-related Macular Degeneration." Retina-Vitreus, 27, ss.158 - 161, 2018. |
| ISNAD | KILIÇ, Raşit vd. "Serum Endocan Levels in Patients with Age-related Macular Degeneration". Retina-Vitreus 27/2 (2018), 158-161. |
